S&P 500   4,234.48 (-1.26%)
DOW   33,062.25 (-1.11%)
QQQ   355.95 (-1.47%)
AAPL   172.18 (-0.90%)
MSFT   313.64 (-2.54%)
META   301.04 (-1.88%)
GOOGL   132.79 (-1.03%)
AMZN   125.50 (-3.06%)
TSLA   249.01 (-1.03%)
NVDA   439.28 (-1.91%)
NIO   8.75 (-0.46%)
BABA   84.86 (-1.93%)
AMD   100.83 (-2.36%)
T   14.64 (-0.20%)
F   12.15 (-1.30%)
MU   68.60 (+0.94%)
CGC   0.70 (-5.09%)
GE   107.93 (-0.79%)
DIS   79.89 (-2.18%)
AMC   8.06 (-1.10%)
PFE   33.90 (-0.12%)
PYPL   57.77 (-1.35%)
NFLX   378.96 (-0.36%)
S&P 500   4,234.48 (-1.26%)
DOW   33,062.25 (-1.11%)
QQQ   355.95 (-1.47%)
AAPL   172.18 (-0.90%)
MSFT   313.64 (-2.54%)
META   301.04 (-1.88%)
GOOGL   132.79 (-1.03%)
AMZN   125.50 (-3.06%)
TSLA   249.01 (-1.03%)
NVDA   439.28 (-1.91%)
NIO   8.75 (-0.46%)
BABA   84.86 (-1.93%)
AMD   100.83 (-2.36%)
T   14.64 (-0.20%)
F   12.15 (-1.30%)
MU   68.60 (+0.94%)
CGC   0.70 (-5.09%)
GE   107.93 (-0.79%)
DIS   79.89 (-2.18%)
AMC   8.06 (-1.10%)
PFE   33.90 (-0.12%)
PYPL   57.77 (-1.35%)
NFLX   378.96 (-0.36%)
S&P 500   4,234.48 (-1.26%)
DOW   33,062.25 (-1.11%)
QQQ   355.95 (-1.47%)
AAPL   172.18 (-0.90%)
MSFT   313.64 (-2.54%)
META   301.04 (-1.88%)
GOOGL   132.79 (-1.03%)
AMZN   125.50 (-3.06%)
TSLA   249.01 (-1.03%)
NVDA   439.28 (-1.91%)
NIO   8.75 (-0.46%)
BABA   84.86 (-1.93%)
AMD   100.83 (-2.36%)
T   14.64 (-0.20%)
F   12.15 (-1.30%)
MU   68.60 (+0.94%)
CGC   0.70 (-5.09%)
GE   107.93 (-0.79%)
DIS   79.89 (-2.18%)
AMC   8.06 (-1.10%)
PFE   33.90 (-0.12%)
PYPL   57.77 (-1.35%)
NFLX   378.96 (-0.36%)
S&P 500   4,234.48 (-1.26%)
DOW   33,062.25 (-1.11%)
QQQ   355.95 (-1.47%)
AAPL   172.18 (-0.90%)
MSFT   313.64 (-2.54%)
META   301.04 (-1.88%)
GOOGL   132.79 (-1.03%)
AMZN   125.50 (-3.06%)
TSLA   249.01 (-1.03%)
NVDA   439.28 (-1.91%)
NIO   8.75 (-0.46%)
BABA   84.86 (-1.93%)
AMD   100.83 (-2.36%)
T   14.64 (-0.20%)
F   12.15 (-1.30%)
MU   68.60 (+0.94%)
CGC   0.70 (-5.09%)
GE   107.93 (-0.79%)
DIS   79.89 (-2.18%)
AMC   8.06 (-1.10%)
PFE   33.90 (-0.12%)
PYPL   57.77 (-1.35%)
NFLX   378.96 (-0.36%)
Positive News SentimentPositive News
NASDAQ:OPRX

OptimizeRx (OPRX) Stock Forecast, Price & News

$7.15
-0.38 (-5.05%)
(As of 12:33 PM ET)
Compare
Today's Range
$7.14
▼
$7.64
50-Day Range
$7.43
▼
$14.12
52-Week Range
$7.14
▼
$22.77
Volume
29,553 shs
Average Volume
177,867 shs
Market Capitalization
$118.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.60
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

OptimizeRx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
113.4% Upside
$15.60 Price Target
Short Interest
Bearish
4.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.90mentions of OptimizeRx in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.83) to ($0.54) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Computer And Technology Sector

218th out of 603 stocks

Business Services, Not Elsewhere Classified Industry

38th out of 92 stocks

See Top Rated MarketRank™ Stocks Here

OPRX stock logo

About OptimizeRx (NASDAQ:OPRX) Stock

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow. The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems. In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was founded in 2006 and is headquartered in Rochester, Michigan.

OPRX Price History

OPRX Stock News Headlines

September 26, 2023 | finance.yahoo.com
OptimizeRx Unveils a Significant Enhancement to its Omni-channel Healthcare Engagement Platform
September 21, 2023 | finance.yahoo.com
Are OptimizeRx Corporation (NASDAQ:OPRX) Investors Paying Above The Intrinsic Value?
October 3, 2023 | Oxford Club (Ad)
The Ultimate Passive Income Play
The #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas.
August 24, 2023 | finance.yahoo.com
OptimizeRx Expands AI Powered Omnichannel Platform
August 20, 2023 | finance.yahoo.com
OptimizeRx Corporation (NASDAQ:OPRX) Analysts Just Trimmed Their Revenue Forecasts By 13%
August 16, 2023 | marketwatch.com
OptimizeRx Shares Drop 22% As Non-Core Business Drags on Results
August 16, 2023 | msn.com
Stifel Maintains OptimizeRx (OPRX) Buy Recommendation
August 16, 2023 | msn.com
Roth MKM Maintains OptimizeRx (OPRX) Buy Recommendation
October 3, 2023 | Oxford Club (Ad)
The Ultimate Passive Income Play
The #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas.
August 15, 2023 | finanznachrichten.de
OptimizeRx Corporation: OptimizeRx Reports Second Quarter 2023 Financial Results
August 14, 2023 | finance.yahoo.com
OptimizeRx Reports Second Quarter 2023 Financial Results
August 10, 2023 | finance.yahoo.com
Positive Signs As Multiple Insiders Buy OptimizeRx Stock
July 31, 2023 | finance.yahoo.com
OptimizeRx Sets Second Quarter 2023 Conference Call for August 14, 2023 at 4:30 p.m. ET
July 14, 2023 | fool.com
OptimizeRx (NASDAQ: OPRX)
June 30, 2023 | finance.yahoo.com
OptimizeRx Corporation (NASDAQ:OPRX) is a favorite amongst institutional investors who own 85%
June 20, 2023 | finance.yahoo.com
LifeMD Appoints William J. Febbo to its Board of Directors
May 25, 2023 | markets.businessinsider.com
Analysts Offer Insights on Technology Companies: OptimizeRx (OPRX) and UiPath (PATH)
May 25, 2023 | markets.businessinsider.com
SVB Securities Reaffirms Their Buy Rating on OptimizeRx (OPRX)
May 24, 2023 | finance.yahoo.com
OptimizeRx’s CEO Provides 2023 Midyear Strategic Update
May 24, 2023 | finanznachrichten.de
OptimizeRx Corporation: OptimizeRx's CEO Provides 2023 Midyear Strategic Update
May 24, 2023 | benzinga.com
OptimizeRx's CEO Provides 2023 Midyear Strategic Update
May 18, 2023 | finance.yahoo.com
OptimizeRx’s Karina Castagna Named One of the 2023 PM360 ELITE 100
May 18, 2023 | finance.yahoo.com
Revenues Tell The Story For OptimizeRx Corporation (NASDAQ:OPRX)
May 12, 2023 | msn.com
Recap: OptimizeRx Q1 Earnings
May 11, 2023 | markets.businessinsider.com
OptimizeRx (OPRX) Gets a Buy from RBC Capital
May 11, 2023 | finanznachrichten.de
OptimizeRx Corporation: OptimizeRx Reports First Quarter 2023 Financial Results
May 10, 2023 | finance.yahoo.com
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Tops Revenue Estimates
See More Headlines
Receive OPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

OPRX Company Calendar

Last Earnings
8/14/2023
Today
10/03/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Sector
Computer and Technology
Current Symbol
NASDAQ:OPRX
CUSIP
N/A
CIK
1448431
Web
www.optimizerx.com
Phone
(248) 651-6568
Fax
248-453-5529
Employees
109
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.60
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+107.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-11,440,000.00
Net Margins
-23.30%
Pretax Margin
-23.29%
Return on Equity
-10.05%
Return on Assets
-9.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.44
Quick Ratio
15.44

Sales & Book Value

Annual Sales
$62.45 million
Price / Sales
2.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.35 per share
Price / Book
1.02

Miscellaneous

Outstanding Shares
16,640,000
Free Float
15,906,000
Market Cap
$125.30 million
Optionable
Not Optionable
Beta
1.02
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. William J. FebboMr. William J. Febbo (Age 54)
    CEO & Director
    Comp: $694.4k
  • Mr. Edward Stelmakh C.M.A. (Age 57)
    M.B.A., MBA, CFO & COO
    Comp: $547.05k
  • Mr. Stephen L. SilvestroMr. Stephen L. Silvestro (Age 45)
    Chief Commercial Officer
    Comp: $458.6k
  • Mr. Andrew Jacob D'Silva
    Sr. VP of Corp. Fin.
  • Mr. Todd Inman (Age 67)
    Chief Technology Officer
  • Ms. Marion K Odence-Ford (Age 58)
    Gen. Counsel & Chief Compliance Officer
  • Maira Alejandra
    Media Relations Mang.
  • Ms. Sheryl Kearney
    HR Mang.
  • Mr. Terence J. Hamilton (Age 58)
    Sr. VP of Pharma
  • Ms. Rebecca Whitney
    Sr. VP of Commercial Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













OPRX Stock - Frequently Asked Questions

Should I buy or sell OptimizeRx stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPRX shares.
View OPRX analyst ratings or view top-rated stocks.

What is OptimizeRx's stock price forecast for 2023?

8 brokers have issued 1 year price targets for OptimizeRx's shares. Their OPRX share price forecasts range from $13.00 to $20.00. On average, they expect the company's share price to reach $15.60 in the next twelve months. This suggests a possible upside of 107.2% from the stock's current price.
View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts.

How have OPRX shares performed in 2023?

OptimizeRx's stock was trading at $16.80 on January 1st, 2023. Since then, OPRX stock has decreased by 55.2% and is now trading at $7.53.
View the best growth stocks for 2023 here.

When is OptimizeRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our OPRX earnings forecast.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.07. The company had revenue of $13.82 million for the quarter, compared to analyst estimates of $14.97 million. OptimizeRx had a negative net margin of 23.30% and a negative trailing twelve-month return on equity of 10.05%.

What ETFs hold OptimizeRx's stock?

ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD).Global X Telemedicine & Digital Health ETF (EDOC).

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

How do I buy shares of OptimizeRx?

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $7.53.

How much money does OptimizeRx make?

OptimizeRx (NASDAQ:OPRX) has a market capitalization of $125.30 million and generates $62.45 million in revenue each year. The company earns $-11,440,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does OptimizeRx have?

The company employs 109 workers across the globe.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The official website for the company is www.optimizerx.com. The company can be reached via phone at (248) 651-6568, via email at oprx@cma.team, or via fax at 248-453-5529.

This page (NASDAQ:OPRX) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -